partneringRoche drops two Huntington’s programmes from IonisRoche has discontinued two Huntington’s disease programmes after its Ionis-partnered drug tominersen failed to improve patients’ symptoms and a separate candidate raised concerns in animal studi … more ➔
clinical trialAstraZeneca and Ionis miss in key ATTR-CM trialAstraZeneca and Ionis have suffered a major late-stage setback after Wainua/Wainzua (eplontersen) failed to hit the primary endpoint in a phase 3 trial in transthyretin-mediated amyloid cardiomyopathy … more ➔
licensingGSK ends Alector neuroscience deal after trial failuresGSK has pulled out of its neuroscience collaboration with Alector, ending a 2021 alliance that began with a $700m upfront payment but has since been hit by two clinical setbacks. more ➔
fundraisingAlchemab extends Series A with £25m from British Business BankCambridge-based Alchemab Therapeutics has added £25m (€29m) to its Series A financing, taking the round to £109m (€128m) and giving the UK biotech fresh capital to advance its AI-enabled antibody … more ➔
licensingAZ buys ex-China rights to Sino’s COPD drug for $2.1bnAstraZeneca has moved to strengthen its respiratory pipeline with a late-stage Chinese COPD asset, striking a deal that gives it a lower-cost shot at a market MSD recently entered through its $10bn Verona … more ➔
licensingBoehringer licenses PVT virus platform for cancer vaccinesBoehringer Ingelheim has licensed oncology rights to Prime Vector Technologies’ (PVT) Orf virus platform to develop a new generation of cancer vaccines. more ➔
Start-upGraph Therapeutics raises $5m to advance I&I pipelineAustria’s Graph Therapeutics has raised $5m in new financing, bringing its total funding to more than $10m as it advances internal drug discovery programmes in inflammation and immunology built on … more ➔
fundraisingEG 427 rebrands as Cyllene and cashes in €33m Series CFrench gene therapy biotech EG 427 has rebranded as Cyllene Therapeutics and raised €33m in a Series C round to push its lead neuro-urology candidate EG110A toward late-stage clinical testing. more ➔
Scripta TherapeuticsOpinionWhere will AI actually move the needle in drug discovery?Biotech’s biggest opportunity is not simply to generate more compounds faster, but to improve the biological hypotheses behind them and help focused companies turn shared datasets, better models and … more ➔
M&ANovartis buys UK ADC biotech Myricx Bio in up to $1.5bn dealNovartis has agreed to acquire UK-based Myricx Bio for up to $1.5bn, adding a preclinical antibody-drug conjugate platform built around a novel payload class for solid tumours. more ➔
Scripta Therapeutics
